Drug review - Olmesartan medoxomil

Publisher： CSF Medical Communications Ltd

ISSN： 1742-7010

Source： Drugs In Context Primary Care Part B: Cardiovascular Medicine II, Vol.1, Iss.8, 2004-09, pp. : 309-322

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care

Current Hypertension Reviews, Vol. 8, Iss. 3, 2012-08 ,pp. : 190-195

Bentham Science Publishers

Access to resources Recommend Favorite

Olmesartan Medoxomil: As Monotherapy and in Combination Treatment in Hypertension

By Grassi Guido Mancia Giuseppe

High Blood Pressure & Cardiovascular Prevention, Vol. 17, Iss. 1, 2010-03 ,pp. : 1-14

Adis International

Access to resources Recommend Favorite

A Novel Molecule of the Angiotensin II Receptor Blocker Class: Focus on Olmesartan Medoxomil

By Volpe Massimo

High Blood Pressure & Cardiovascular Prevention, Vol. 12, Iss. 2, 2005-01 ,pp. : 79-89

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Safety of Olmesartan Medoxomil in Combination with Glibenclamide in Healthy Volunteers

By Huber Matthias Bolbrinker Juliane Kreutz Reinhold

Clinical and Experimental Hypertension, Vol. 28, Iss. 7, 2006-10 ,pp. : 631-643

Informa Healthcare

Access to resources Recommend Favorite

Reduction of Cardiovascular Risk through Angiotensin II Type 1 Receptor Antagonism: Focus on Olmesartan Medoxomil

By Enrico Agabiti Rosei

High Blood Pressure & Cardiovascular Prevention, Vol. 15, Iss. 4, 2008-01 ,pp. : 231-243

Adis International

Access to resources Recommend Favorite